For the latest COVID-19 Travel restrictions and recommendations please
click hereJoin Europe's leading
Pain Therapeutics Conference, to explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.
The 22nd annual conference will cover the leading advances in
pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the
pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year's agenda, providing an exciting and comprehensive insight into the
pain therapeutics market.
New case studies and regulatory perspectives will bring together the challenges and successes of both pre-clinical and clinical development to equip you with the necessary knowledge to advance the pain therapeutic industry.
Who should attend
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:
- Pain and Migraine
- Inflammation
- Chronic Pain
- Neuropathic Pain
- Analgesic pre-clinical development
- Anaesthesia and Pain Management
- CNS clinical trials
- Ion Channel Pharmacology
- Pharmacology Intelligence
- Translational science
- Drug development
- Exploratory development
Speakers
- Andrea Small-Howard, President & Chief Science Officer, GB Sciences, Inc.
- Arun Bhaskar, President, The British Pain Society
- Barbara Karp, Program Director, EPPIC-Net, National Institutes Of Health
- Candler Paige, Chief Executive Officer, Doloromics
- Christina de Rivera, CSO - companion animal department, Intervivo Solutions
- Domenico Merante, Clinical Development Lead of Nephrology and Orphan Diseases, Vifor Pharma Ltd
- Geert Jan Groeneveld, CSO/CMO, Centre for Human Drug Research
- Ilona Steigerwald, Chief Medical Officer, SVP, Neumentum
- Jennifer Beierlein, Health Program Specialist, National Institute of Neurological Disorders and Stroke National Institutes of Health
- Joshua Cohen, Chief Medical Officer, Braeburn
- Julio Reinecke, Chief Scientific Officer and Co-Founder, Orthogen A G
- Luda Diatchenko, Canada Research Chair in Human Pain Genetics, McGill University
- Lynn Kirkpatrick, President and CEO, Ensysce Biosciences Inc.
- Maria Maiaru, Lecturer in Pharmacology, University of Reading
- Mark J. Field, CEO & Founder, EptivA Therapeutics
- Michael Seminerio, Senior Director, US Medical Lead, Teva Pharmaceuticals
- Neil Singla, Chief Executive Officer, Lotus Clinical Research, LLC
- Peter Wehling, CEO and Founder, Orthogen A G
- Randall Kaye, Chief Medical Officer, Neurana Pharmaceuticals
- Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals
- Ru-Rong Ji, Professor in Anesthesiology, Distinguished Professor of Anesthesiology, Professor in Neurobiology, Professor in Cell Biology, School of Medicine,, Duke Neurobiology
- Steve Fox, Chairman, Akelos Inc
- Todd Krueger, President and CEO, AOBiome
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
